相关实验视频
Updated: Jun 28, 2025

10:10
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
12.7K
基于网络的认知康复干预癌症相关的认知障碍后的化学疗法对侵略性淋巴瘤:一个随机试验试验的协议
Priscilla Gates1,2, Heather J Green3, Karla Gough2,4
1Cognitive Neuroscience Unit, Deakin University, Burwood, Victoria, Australia priscilla.gates@deakin.edu.au.
BMJ open
|April 23, 2024
概括
这项研究测试了基于网络的认知康复计划eReCog,用于有侵略性淋巴瘤的化疗患者. 该试点试验评估了可行性和可接受性,显示了未来干预措施改善与癌症相关的认知障碍的前景.
科学领域:
- 在瘤学瘤学.
- 神经科学是一个神经科学.
- 康复医学 康复医学 康复医学
背景情况:
- 与癌症相关的认知障碍 (CRCI) 显著影响生活质量.
- 现有的CRCI干预措施是有限的,特别是对于血液性恶性瘤.
- 癌症幸存者需要有效,可访问的认知支持策略.
研究的目的:
- 为了评估基于网络的认知康复计划的可行性和可接受性,eReCog.
- 评估招募,保留和坚持的方法,为最终的试验.
- 探索eReCog在改善淋巴瘤患者化疗后认知功能方面的潜在疗效.
主要方法:
- 试点随机对照试验,共有38名参与者.
- 参与者接受了常规护理或eReCog加常规护理.
- eReCog是一个为期4周的在线课程,包括心理教育和技能培训.
主要成果:
- 该研究评估了招聘和留住员工的可行性.
- 评估了对eReCog的坚持,可用性和参与者的动机.
- 收集了关于eReCog潜在疗效的初步数据.
结论:
- 试点试验为eReCog.提供了可行性和可接受性数据.
- 这些发现将为为淋巴瘤患者提供eReCog的最终试验提供信息.
- eReCog显示出作为癌症相关认知障碍的干预措施的潜力.
相关概念视频
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

